Saturday, August 8, 2026

Partial bypass of frataxin deficiency by ISCU M141I restores cytosolic and nuclear Fe–S cluster assembly

›
Mosbach, V., Maio, N., Hermet, L. et al. Partial bypass of frataxin deficiency by ISCU M141I restores cytosolic and nuclear Fe–S cluster ass...

Autophagy activation by urolithin-a derivative UA-36 mitigates Friedreich's ataxia pathologies induced by frataxin deficiency

›
Gong Q, Liu T, Han X, Zhang R, Liu X, Xiong B, Ali T, Huang J, Xie Y, Li S, Yang X. Autophagy activation by urolithin-a derivative UA-36 mit...
Wednesday, August 5, 2026

Visual Pathways Involvement in Friedreich’s Ataxia Patients Without Macular Impairment

›
Parisi, V.; Barbano, L.; Di Renzo, A.; Dell’Aquila, C.; D’Andrea, M.; Castelluzzo, A.M.; Colacino, G.; Gioiosa, V.; Coppola, G.; Casali, C.;...

BRD4 recruitment into HP1 condensates desilences transcription without erasure of repressive chromatin

›
Brandon, C.J., Robinson-Thiewes, S., Kaulage, M. et al. BRD4 recruitment into HP1 condensates desilences transcription without erasure of re...

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

›
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar). “Open label (OL) study data announced in June furt...
Tuesday, August 4, 2026

Stem Cell Transplantation in Friedreich Ataxia: Cure for Leukemia but No Effect on Neurological Progression

›
A. Gitman, N. Bhandari, M. Castellaro, K. Schadt, M. Cancio, and D. R. Lynch, “ Stem Cell Transplantation in Friedreich Ataxia: Cure for Leu...

Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic

›
Jul 29, 2026. SAN FRANCISCO--(BUSINESS WIRE)--Adjuvia Therapeutics, a biotechnology company developing therapeutics to treat mitochondrial d...

Goldenrod Therapeuticsare committed to developing a next-generation phosphodiesterase 4 (PDE4) inhibitor designed to address serious neurological conditions, including Friedreich’s ataxia

›
Goldenrod Therapeutics is a portfolio company of Fannin based in Houston, Texas. We are committed to developing a next-generation phosphodie...

Neurophysiological assessment of disease severity in Friedreich’s Ataxia: a study of brainstem auditory and visual evoked potentials

›
Maccora S, Quartetti U, Lima SM, Rini N, Cucchiara M, Agnello L, Gambino CM, Brighina F, Ciaccio M, Di Stefano V. Neurophysiological assessm...

Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension

›
Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension. Huang, Chuangjia, Bai, June, Luo, Ang, Yan...